A Tool to Predict Tuberculosis Drug Resistance Now Available Online
|
By LabMedica International staff writers Posted on 09 Jun 2015 |
|
![Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2015-06-09/GMS-170.jpg "Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).")
Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - [US] Centers for Disease Control and Prevention).
A new online tool for the rapid analysis of whole genome sequence data is set to aid clinicians predict whether a particular patient's tuberculosis (TB) will be susceptible to frequently prescribed antibiotics.
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
The World Health Organization (WHO) estimated that 5% of the world's 11 million tuberculosis patients have multi-drug-resistance disease (MDR-TB) and that 480,000 new cases arose during 2013 alone. Of those approximately 9% have extensively resistant tuberculosis (XDR-TB) where, in addition to resistance to at least both of the major first line drugs (isoniazid and rifampicin), they also have resistance to two classes of second line drugs used to treat MDR-TB (the fluoroquinolones and the injectable drugs, amikacin, kanamycin, or capreomycin).
Current molecular tests examine limited numbers of mutations in Mycobacterium tuberculosis, the organism that causes TB, and although whole genome sequencing could fully characterize drug resistance, the complexity of data obtained by this technology has restricted their clinical application.
To help solve this problem investigators at the London School of Hygiene & Tropical Medicine (United Kingdom) have created an online tool that analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB. Initially, a library (1,325 mutations) predictive of drug resistance for 15 anti-tuberculosis drugs was compiled and then validated for 11 of them using genomic-phenotypic data from 792 strains. A rapid online "TB-Profiler" tool was developed to report drug resistance and strain-type profiles directly from raw sequences. The TB-Profiler tool is available on the Internet (Please see Related Links below).
Senior author Dr. Taane Clark, reader in genetic epidemiology and statistical genomics at the London School of Hygiene & Tropical Medicine, said, "Sequencing already assists patient management for a number of conditions such as HIV, but now that it is possible to sequence M. tuberculosis from sputum from suspected multi-drug resistance patients means it has a role in the management of tuberculosis. We have developed a prototype to guide treatment of patients with drug resistant disease, where personalized medicine and treatment offers improved rates of cure."
Complete information regarding the new online tool was published in the May 27, 2015, online edition of the journal Genome Medicine.
Related Links:
TB-Profiler tool
London School of Hygiene & Tropical Medicine
New
Gold Member
Aspiration System
VACUSAFE
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Latest Microbiology News
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read more
Molecular Diagnostics
view channel
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read more
Plasma ctDNA Testing Predicts Breast Cancer Recurrence After Neoadjuvant Therapy
Accurate identification of breast cancer patients at risk of relapse after pre-surgery treatment is central to guiding adjuvant decisions, particularly in aggressive disease. Circulating fragments of tumor... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read more
Pathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read more
Technology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read more
Industry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more
